Federal Project Grant Award Summary

The University of Texas MD Anderson Cancer Center received a $483,354 project grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a three-year performance period beginning June 1, 2026. The award supports the development of spatial machine learning algorithms and an artificial intelligence (AI) copilot system designed to enable early interception and detection of lung precancer. This research initiative aligns with the DHA's strategic focus on transforming healthcare through innovative medical solutions and represents the agency's investment in precision medicine and cancer prevention technologies that have potential applications for military service members and the broader public.

The project deliverables include advanced computational tools and methodologies that leverage machine learning and AI technologies to identify precancerous lung lesions at earlier stages of disease progression, thereby improving clinical outcomes through timely intervention. As a National Cancer Institute-designated Comprehensive Cancer Center with established expertise in translational research and clinical trial management, MD Anderson brings substantial capabilities in cancer detection, biomarker development, and clinical implementation to this research initiative. The three-year award period extends through May 31, 2029, with performance conducted at MD Anderson's Houston, Texas location.